We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Childhood Hereditary Spherocytosis Confirmed by Hematology Analyzer

By LabMedica International staff writers
Posted on 25 Feb 2015
The hallmark of hereditary spherocytosis (HS) is a decreased surface area-to-volume ratio of the erythrocytes (RBC), resulting in the characteristic spherocyte form and in a blood film, spherocytes have a smaller diameter than normal RBC and are hyperchromic.


The flow cytometric eosin-5′-maleimide test (EMA) is highly sensitive and specific for HS as a confirmatory method and the utility of hyperchromic erythrocytes in HS screening and evaluation of the EMA test performed on a hematology analyzer was compared with the reference method.

Hematologists at Our Lady's Children's Hospital (Crumlin, Dublin, Ireland) analyzed blood samples from 740 pediatric patients presenting at their institution in the reticulocyte mode of the CELL-DYN Sapphire hematology analyzer (Abbott Diagnostics; Wiesbaden-Delkenheim, Germany) to obtain hyperchromic erythrocyte counts. More...
The EMA test used as a reference for the laboratory diagnosis of HS was performed on a FACSCanto II flow cytometer (Becton Dickinson; San Jose, CA, USA).

Hyperchromic erythrocytes were the highest in patients with HS (median 11.5%; range 5.1 to 29.2%). Patients with autoimmune hemolytic disease had significantly less hyperchromic erythrocytes (median 4.9%; range 0.0 to 18.3%). Hyperchromic erythrocytes showed a high area under the receiver operating characteristic (ROC) curve of 0.972. At 4.9% cut-off, hyperchromic erythrocytes detected HS with 96.4% sensitivity and 99.1% specificity. The EMA test on CELL-DYN Sapphire correlated strongly with the reference test and had identical diagnostic power. Stability studies with blood from HS patients showed a significant decrease in hyperchromic erythrocytes after six hours of storage.

The authors concluded that measurement of hyperchromic erythrocytes is highly sensitive and specific for detecting HS and can be used for rapid and inexpensive screening. If required, the EMA test can be performed on the CELL-DYN Sapphire or a standard flow cytometer for confirmation of HS. The study was published in the February 2015 issue of the International Journal of Laboratory Hematology.

Related Links:

Our Lady's Children's Hospital 
Abbott Diagnostics 
Becton Dickinson



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Hematology Consumables
Bioblood Devices
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.